quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

AGNC (AGNC) Q3 2024 Earnings Call Transcript

View original at finance.yahoo.com
AGNC (AGNC) Q3 2024 Earnings Call Transcript Image source: The Motley Fool. Date Oct. 22, 2024 • 8:30 a.m…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Consumer credit is divided with lower income pressure but no significant distress

    80% confidence
  • Election volatility is expected through November with defensive positioning via delta hedging

    80% confidence
  • Servicing capacity is not an issue for mortgage refinancing

    80% confidence
  • Net spread and dollar roll income has been well over the dividend for a couple of years and is not a driver of dividend policy

    80% confidence
  • Agency MBS supply is expected to increase modestly with lower rates

    80% confidence
  • Recent refinancing wave was short-lived and response was less aggressive than during COVID for the same incentive

    80% confidence
  • The likely scenario is that primary mortgage rates stay above 6.5% for an extended period

    80% confidence
  • 68% unencumbered capacity gives ability to raise leverage once spread range confidence and election volatility pass

    80% confidence
  • Basel III endgame resolution is expected to be delayed from late Q3

    80% confidence
  • Federal Reserve projects 250 basis points decline in fed funds rate by end of 2026

    80% confidence
  • The investment environment is promising and durable, characterized by mortgage spreads materially wider than historical norms, declining interest-rate volatility, and emerging accommodative monetary policy

    80% confidence
  • Production coupons offer the best long-run risk-adjusted returns

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
AGNC (AGNC) Q3 2024 Earnings Call Transcript — Source | Via News | pt.VIA.NEWS